MODERNA has announced a memorandum of understanding (MoU) with the Canadian Government to build a state-of-the-art mRNA vaccine manufacturing facility in Canada, which could help combat diseases including Covid-19.
Biotechnology company Moderna claims to be pioneering mRNA therapeutics and vaccines. Its mRNA platform has allowed development of therapeutics and vaccines for autoimmune diseases, cardiovascular diseases, immuno-oncology, infectious diseases, and rare diseases.
The MoU is aimed at building the foundation to support Canada with direct access to pandemic response capabilities and provide access to Moderna vaccines in development for respiratory viruses. It would see Canadians provided with access to a domestically manufactured portfolio of mRNA vaccines against viruses including Covid-19, seasonal flu, respiratory syncytial virus (RSV), and other potential vaccines, pending licensure.
In urgent situations, the facility would be activated to support Canada with rapid pandemic response capabilities.
The agreement includes access to Moderna’s mRNA development engine. The company’s mRNA early development engine services are structured to deliver high-quality mRNA drugs from development candidate nomination to human proof-of-concept data.
According to Patricia Gauthier, Moderna’s Canadian General Manager, the agreement continues the company’s long-term collaboration with Canada.
Moderna is in discussions with other governments about potential collaborations built on a similar model. Stéphane Bancel, CEO of Moderna said that the company believes the business model will have global impact and implications.
Catch up on the latest news, views and jobs from The Chemical Engineer. Below are the four latest issues. View a wider selection of the archive from within the Magazine section of this site.